Skip to main content

Table 1 The clinical features of CLL/SLL patients

From: The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center

Case Age/sex Time (months) Scr (μmol/L) UTP (g/24 h) MIg Cryo C3 (g/L) C4 (g/L) ER-IO Treatment F. time (months) Renal outcome CLL/SLL
1 67/M 2 118 10.35 IgMλ Trace 0.57↓ 0.12 LN CYC, CsA 56 Not recovery Stable
2 66/M 0 616 0.80 Negative Trace 0.63 0.26 LN, BM Supportive 52 ESRD (never recovered) Stable
3 58/F 0 95 1.15 IgGκ Negative 0.92 0.21 BM COP, Rituximab Ibrutinib 32 Completely recovery Improved
4 58/F 0 174 0.48 IgMκ Negative 0.48↓ 0.05↓ LN,BM RFC 31 Completely recovery Stable
5 66/F 60 570 0.87 Negative NA 0.72 0.34 LN, Spleen BM CHOP, Ibrutinib 15 Partial recovery Stable
6 62/M 36 118 4.27 IgGκ IgGκ 0.57↓ 0.09↓ LN,BM COP, Ibrutinib 8 Completely recovery Stable
7 68/F 18 456 2.17 Negative NA 0.81 0.16 LN, Prednisone 6 Partial recovery Improved
8 59/F 0 377 0.59 IgMκ Type II 0.46↓ 0.02↓ LN,BM PE for TMA 33 Partial recovery Progressed
9 73/M 3 161 1.44 Negative Negative 0.76 0.20 BM Supportive 2 Not recovery Stable
10 67/M 0 221 12.8 IgMκ IgMκ 0.244↓ 0.06↓ LN,BM Ibrutinib 1 Partial recovery Stable
  1. Notes: Time: time from diagnosis of CLL/SLL to renal biopsy; Scr: serum creatinine at renal biopsy
  2. Abbreviations: UTP urine total protein, MIg monoclonal immunoglobulin determined by serum/urine immunofixation electrophoresis; Cryo cryoglobulinemia, ER-IO extra-renal involved organs, F.time follow up time, LN lymph node, BM bone marrow, CYC cyclophosphamide, CsA cyclosporine, ESRD end stage renal disease, COP cyclophosphamide, vincristine, and prednisone, RFC rituximab, fludarabine and cyclophosphamide, CHOP cyclophosphamide, doxorubicin, vincristine and prednisone, PE plasma exchange, TMA thrombotic microangiopathy